Showing results for:
Vincristine is an FDA-approved chemotherapy agent that is used to treat some types of blood cancer as well as some noncancerous conditions. Vincristine may cause hair loss in some patients. After treatment with vincristine has ended, or sometimes even during treatment, normal hair growth should return.
Oncovin® Vincristine
Vincristine sulfate liposome injection
Vincristine sulfate liposome injection is FDA approved for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.
Marqibo®
Vincristine sulfate liposome injection
Vorinostat is FDA approved to treat cutaneous T-cell lymphoma (CTCL) in patients whose CTCL gets worse, does not go away or comes back after treatment with two systemic therapies.
Zolinza® Vorinostat
Zanubrutinib is indicated for the treatment of adult patients with:Mantle cell lymphoma (MCL) who have received at least one prior therapy.This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.Waldenström’s macroglobulinemia (WM)Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy.This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Brukinsa® Zanubrutinib
Zoledronic acid is FDA approved to treat hypercalcemia (high levels of blood calcium) that may occur in patients with some types of cancer, including myeloma. It is also FDA approved along with chemotherapy to treat bone damage caused by myeloma or by cancer that began in another part of the body but has spread to the bones.
Zometa® Zoledronic acid